Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: Background, rationale, and study protocol

Transplantation Research

Volumn 2, Issue 1, 2013, Pages

  Haynes, Richard ^a   Baigent, Colin ^a   Harden, Paul ^b   Landray, Martin ^a   Akyol, Murat ^c   Asderakis, Argiris ^d   Baxter, Alex ^a   Bhandari, Sunil ^e,y   Chowdhury, Paramit ^f,x   Clancy, Marc ^g   Emberson, Jonathan ^a,af   Gibbs, Paul ^h,ad   Hammad, Abdul ^i,ab   Herrington, Will ^a   Jayne, Kathy ^a   Jones, Gareth ^j,ae   Krishnan, Nithya ^k   Lay, Michael ^a   Lewis, David ^a   Macdougall, Iain ^l,z   Nathan, Chidambaram ^m   Neuberger, James ⁿ   Newstead, Chas ^o,aa   Pararajasingam, Ravi ^p,ac   Puliatti, Carmelo ^q   Rigg, Keith ^r   Rowe, Peter ^s   Sharif, Adnan ^t,w   Sheerin, Neil ^u   Sinha, Sanjay ^b   Watson, Chris ^v   Friend, Peter ^b   Morris, Peter ^af   Wheatley, Keith ^af   Abramowicz, Daniel ^af   Blackwell, Lisa ^af   Fifer, L ^w   Waite, C ^w   Walmsley Allen, N ^w   Torpey, N ^v   O'Sullivan, A M ^v   Webley, Y ^d   Higgins, R ^k   Davidson, J ^c   Steven, J ^c   McLaren, B ^g   McGregor, L ^g   Kelly, D ^g   Watkins, J ^x   James, K ^y   Stark, H ^y   Cathcart, T ^y   Sharples, F ^z   Baker, R ^aa   Giddings, E ^aa   Wheatley, R ^aa   Turner, S ^aa   Tobin, K ^aa   Heyworth, S ^ab   Riad, H ^ac   Pereira, A ^ac   Flynn, R ^ac   Griffin, C ^ac   Playford, M ^u   Boughen, B ^u   Byrne, C ^r   Boswell, A ^r   Brockmann, J ^b   Ruse, S ^b   Weetman, M ^b   Ingell, J ^b   Watson, L ^b   De Veciana, A ^b   Coles, M ^s   Pickering, C ^s   Watkins, L ^ad   Williams, F ^ad   Kinyanjui, R ^j   Curran, D ^j   Deelchand, V ^j,q   Rolfe, C ^q   Smith, J ^q   McKane, W ^m   Edwards, L ^m   Okhuoya, F ^m   King, C ^m   Griffiths, L ^ae   Davis, R ^af   Bahu, T ^af   Bateman, S ^af   Collett, A ^af   Cobb, L ^af   Fathers, S ^af   Al Saidi, R ^af   Barton, I ^af   Bu, Y ^af   Cleverley, P ^af   Craig, M ^af   Delmestri, A ^af   Harding, P ^af   Tochlin, S ^af   Goodenough, B ^af   Coates, G ^af   Cui, G ^af   Daniels, C ^af   more..

^a CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^e HULL ROYAL INFIRMARY   (United Kingdom)

^f GUY S HOSPITAL   (United Kingdom)

^g WESTERN INFIRMARY   (United Kingdom)

^h QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

ⁱ ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^j ROYAL FREE HOSPITAL   (United Kingdom)

^k UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^l KING S COLLEGE HOSPITAL   (United Kingdom)

^m NORTHERN GENERAL HOSPITAL   (United Kingdom)

ⁿ NHS BLOOD AND TRANSPLANT   (United Kingdom)

^o ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^p MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^q ROYAL LONDON HOSPITAL   (United Kingdom)

^r NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^s DERRIFORD HOSPITAL   (United Kingdom)

^t QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^u FREEMAN HOSPITAL   (United Kingdom)

^v ADDENBROOKE S HOSPITAL   (United Kingdom)

^w UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^x GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^y HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^z KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^aa LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^ab ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^ac MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^ad PORTSMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^ae YORK TEACHING HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^af Nottingham University Hospitals NHS Trust ^*

more..

Author keywords

Alemtuzumab; Basiliximab; Campath; Kidney transplantation; Randomized controlled trial; Sirolimus; Tacrolimus

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CALCINEURIN INHIBITOR; CHLORPHENIRAMINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ADULT; ARTICLE; BIOPSY; CHRONIC ALLOGRAFT NEPHROPATHY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; HUMAN; HUMAN TISSUE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); MULTICENTER STUDY; NEPHROTOXICITY; OPEN STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; YOUNG ADULT;

EID: 84896731664     PISSN: None     EISSN: 20471440     Source Type: Journal    
DOI: 10.1186/2047-1440-2-7     Document Type: Article

References (30)

1. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LYC, Held PJ, Port FK. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant 10.1056/NEJM199912023412303. N Eng J Med 1999, 341(23):1725-1730.
2. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies?. Am J Transplant 2004, 4(8):1289-1295. 10.1111/j.1600-6143.2004.00515.x, 15268730.
3. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrology: JASN 2005, 16(10):3015-3026.
4. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Eng J Med 2003, 349(24):2326-2333.
5. Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A, Margreiter R, Hugo C, Grinyo JM, Frei U. Reduced exposure to calcineurin inhibitors in renal transplantation. N Eng J Med 2007, 357(25):2562-2575.
6. Friend PJ, Rebello P, Oliveira D, Manna V, Cobbold SP, Hale G, Jamieson NV, Jamieson I, Calne RY, Harris DT. Successful treatment of renal allograft rejection with a humanized antilymphocyte monoclonal antibody. Transplant Proc 1995, 27(1):869-870.
7. Huang E, Cho Y, Shah T, Peng A, Hayashi R, Bunnapradist S. Alemtuzumab induction in living donor kidney transplantation a multivariate analysis of the optn/ unos database. Transplantation 2006, 82(1 Suppl 2):375-376.
8. Morgan RD, O'Callaghan JM, Knight SR, Morris PJ. Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis. Transplantation 2012, 93(12):1179-1188. 10.1097/TP.0b013e318257ad41, 22660659.
9. Hanaway MJ, Woodle ES, Mulgaonkar S, Peddi VR, Kaufman DB, First MR, Croy R, Holman J. Alemtuzumab induction in renal transplantation. N Eng J Med 2011, 364(20):1909-1919.
10. Flechner SM. Reviewing the evidence for de novo immunosuppression with sirolimus. Transplant Proc 2008, 40(10 Suppl):S25-S28.
11. Schena FP, Pascoe MD, Alberu J, del Carmen RM, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009, 87(2):233-242. 10.1097/TP.0b013e3181927a41, 19155978.
12. Lebranchu Y, Thierry A, Toupance O, Westeel PF, Etienne I, Thervet E, Moulin B, Frouget T, Le Meur Y, Glotz D. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 2009, 9(5):1115-1123. 10.1111/j.1600-6143.2009.02615.x, 19422337.
13. Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011, 377(9768):837-847. 10.1016/S0140-6736(10)62318-5, 21334736.
14. Lebranchu Y, Thierry A, Thervet E, Buchler M, Etienne I, Westeel PF, de Ligny HB, Moulin B, Rerolle JP, Frouget T. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the Postconcept study. Am J Transplant 2011, 11(8):1665-1675. 10.1111/j.1600-6143.2011.03637.x, 21797975.
15. Li Y, Zheng XX, Li XC, Zand MS, Strom TB. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation 1998, 66(10):1387-1388. 10.1097/00007890-199811270-00021, 9846527.
16. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994, 12:991-1045. 10.1146/annurev.iy.12.040194.005015, 8011301.
17. Kirk AD, Mannon RB, Kleiner DE, Swanson JS, Kampen RL, Cendales LK, Elster EA, Wakefield T, Chamberlain C, Hoffmann SC. Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation 2005, 80(8):1051-1059. 10.1097/01.tp.0000174341.49741.8f, 16278585.
18. Tan HP, Kaczorowski DJ, Basu A, Unruh M, McCauley J, Wu C, Donaldson J, Dvorchik I, Kayler L, Marcos A. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2006, 6(10):2409-2417. 10.1111/j.1600-6143.2006.01495.x, 3154761, 16889606.
19. Barth RN, Janus CA, Lillesand CA, Radke NA, Pirsch JD, Becker BN, Fernandez LA, Thomas Chin L, Becker YT, Odorico JS. Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transpl Int 2006, 19(11):885-892. 10.1111/j.1432-2277.2006.00388.x, 17018123.
20. Calne R, Moffatt SD, Friend PJ, Jamieson NV, Bradley JA, Hale G, Firth J, Bradley J, Smith KG, Waldmann H. Prope tolerance with induction using Campath 1H and low-dose cyclosporin monotherapy in 31 cadaveric renal allograft recipients. Nippon Geka Gakkai Zasshi 2000, 101(3):301-306.
21. Valmori D, Tosello V, Souleimanian NE, Godefroy E, Scotto L, Wang Y, Ayyoub M. Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T cells. J Immunol 2006, 177(2):944-949.
22. Wells AD, Li XC. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999, 5:1303. 10.1038/15260, 10545998.
23. Bloom DD, Hu H, Fechner JH, Knechtle SJ. T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients. Transplantation 2006, 81(1):81-87. 10.1097/01.tp.0000191940.13473.59, 16421481.
24. Gallon L, Gagliardini E, Benigni A, Kaufman D, Waheed A, Noris M, Remuzzi G. Immunophenotypic analysis of cellular infiltrate of renal allograft biopsies in patients with acute rejection after induction with alemtuzumab (Campath-1H). Clin J Am Soc Nephrol 2006, 1(3):539-545. 10.2215/CJN.01741105, 17699257.
25. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130(6):461-470. 10.7326/0003-4819-130-6-199903160-00002, 10075613.
26. Mulay AV, Cockfield S, Stryker R, Fergusson D, Knoll GA. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation 2006, 82(9):1153-1162. 10.1097/01.tp.0000237101.58974.43, 17102766.
27. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985, 27(5):335-371. 10.1016/S0033-0620(85)80003-7, 2858114.
28. Matas AJ. Chronic progressive calcineurin nephrotoxicity: an overstated concept. Am J Transplant 2011, 11(4):687-692. 10.1111/j.1600-6143.2011.03505.x, 3342642, 21446973.
29. Chapman JR. Chronic calcineurin inhibitor nephrotoxicity-lest we forget. Am J Transplant 2011, 11(4):693-697. 10.1111/j.1600-6143.2011.03504.x, 21446974.
30. Noris M, Casiraghi F, Todeschini M, Cravedi P, Cugini D, Monteferrante G, Aiello S, Cassis L, Gotti E, Gaspari F. Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrology: JASN 2007, 18(3):1007-1018.